CTCPROTEOMIC

Single cell proteomics for studying circulating tumor cells and monitor disease progression on breast cancer patients

Coordinatore	IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE    more  Organization address address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD city: LONDON postcode: SW7 2AZ contact info Titolo: Ms. Nome: Brooke Cognome: Alasya Email: send email Telefono: +44 207 594 1181 Fax: +44 207 594 1418
Nazionalità Coordinatore	United Kingdom [UK]
Totale costo	200˙371 €
EC contributo	200˙371 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2011-IEF
Funding Scheme	MC-IEF
Anno di inizio	2012
Periodo (anno-mese-giorno)	2012-09-03   -   2014-09-02

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE  Organization address address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD city: LONDON postcode: SW7 2AZ contact info Titolo: Ms. Nome: Brooke Cognome: Alasya Email: send email Telefono: +44 207 594 1181 Fax: +44 207 594 1418	UK (LONDON)	coordinator	200˙371.80

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'The planned research is aimed at the proteomic analysis at single cell level for circulating tumor cells (CTCs), as these cells shed from the primary tumor site and are identified in transit within the bloodstream of cancer patients with metastatic degree of the disease. The proposed work have an highly multidisciplinar approach to engage the central challenge of our proposal, combining proteomic analysis, microfluidic antibody capture chips and a ‘full optical’ platform which accounts for cell manipulation, cell lysis and protein’s quantification with a level of sensitivity down to proteins copy number. Milestone of the project in carrying out analysis at single cell level, is the comprehensive proteomic study of cell-to-cell variations for the expression of cancer biomarkers, which ultimately led to the heterogeneity, complexity and evolution at phenotypic level of the disease. By the analysis of circulating tumour cells isolated from the peripheral blood of breast cancer patients, we will focus the attention on the quantification of the free form of estrogen receptor and its phoshpotypes, as a unvaluable biomarker directly involved in cellular proliferation and actually targeted by endocrine therapies in clinical practice. Thus, estrogen receptor will be embedded in a platform for multiplex proteomic analysis at single cell level with other four biomarkers. Information achieved by analysis of CTCs will be directly correlate with the status of cells at primary tumor site and the overall status of the disease. Results are expected to provide new insights into tumour cell biology and will offer a new non-invasive tool to monitor the evolution and the progression of the disease, as well the response to therapies during treatment and follow-up of patients.'